Summary

The molecular infectious disease testing market is projected to reach USD 17.78 billion in 2029 from an estimated value of USD 9.37 billion in 2024 at a CAGR of 13.7% during the forecast period. Rapid advancements in molecular diagnostic technologies are the main driving force in the molecular infectious disease testing market. Advancements in PCR, next-generation sequencing, and other technologies enhance test accuracy, speed of completion, and efficiency, making them more accessible at lower costs. Moreover, market players continue to develop high- end automated diagnostic platforms which further improves the workflow and increases diagnostic capabilities. This leads to accurate and timely diagnosis of infectious diseases, improved patient results, and improved surveillance of newly emerging pathogens. Through this, providers can make timely decisions, increasing the adoption rate of molecular diagnostics for infectious disease testing.
“Laboratory tests segment is expected to witness the fastest growth rate in the molecular infectious disease testing market, by test type, during the forecast period.”
Based on test type, the molecular infectious disease testing market can be divided into laboratory tests and point of care tests. Laboratory tests are the fastest-growing segment by test type in the molecular infectious disease testing market because of their high accuracy, scalability, and ability to handle all types of pathogens. These tests, including PCR and sequencing-based diagnostics, are widely used in hospitals and diagnostic laboratories for their precision in discovering infections. With the advances in laboratory automation and high-throughput technologies, turnaround times have decreased significantly, thereby making the laboratory-based molecular tests very efficient. Moreover, the need for extensive diagnostic panels that allow detection of multiple infections in one test further enhances the preference for laboratory-based solutions. With high reliability and the capability to address complex diagnostic needs, laboratory tests are the preferred solution for healthcare providers.
“Multiplex testing segment accounted for the largest market share in the molecular infectious disease testing market, by type, in 2023.”
Based on type, the molecular infectious disease testing market is bifurcated into singleplex testing and multiplex testing. The multiplex testing segment leads the molecular infectious disease testing market due to the capability of its ability to perform multiple tests for detecting and differentiating several pathogens in a single test. This efficiency cuts down time, costs, and resources for diagnosis, thus becoming one of the most preferred options by healthcare providers. All these factors together with the rise in co-infections, necessity for thorough diagnosis solutions, and demand for timely and accurate results have increased the multiplex testing market. In addition, new technology improvements include greater assay sensitivity and the introduction of user-friendly platforms that support widespread use of multiplex testing in hospitals and diagnostic labs.
“Asia Pacific: The fastest-growing market for molecular infectious disease testing”
The worldwide market for molecular infectious disease testing is categorized into North America, Europe, Asia Pacific, Latin America, Middle East & Africa, and the GCC countries. The Asia Pacific region is experiencing significant growth in the molecular infectious disease testing market driven by the growing incidence of infectious diseases in the densely populated countries, together with growing awareness of the early detection of diseases, which has created a demand for more advanced diagnostics. Governments and healthcare organizations throughout the region are investing heavily to improve healthcare infrastructure, expand diagnostic capabilities, and support research initiatives. Moreover, growing emphasis on diseases surveillance and outbreak management and rising healthcare spending position Asia Pacific as one of the big contributors to growth in the entire market.
The break-up of the profile of primary participants in the molecular infectious disease testing market:
• By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 – 30%
• By Designation: C-level - 27%, D-level - 18%, and Others - 55%
• By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America – 6%, and Middle East & Africa- 4%
The key players in this market are Danaher (US), F. Hoffmann-La Roche Ltd (Switzerland), bioMérieux (France), Hologic, Inc. (US), Abbott (US), Thermo Fisher Scientific Inc. (US), QIAGEN (Netherands), Revvity (US), Siemens Healthineers AG (Germany), BD (US), Grifols, S.A. (Spain), QuidelOrtho Corporation (US), DiaSorin S.p.A. (Italy), Bruker (US), Seegene Inc. (South Korea), Genetic Signatures (Australia), Co-Diagnostics, Inc. (US), Savyon Diagnostics (Israel), Vela Diagnostics (Singapore), Molbio Diagnostics Pvt. Ltd. (India), Uniogen OY (Finland), geneOmbio Technologies (India), Advanced Molecular Diagnostics (UK), GeneFirst Limited (UK), and altona Diagnostics GmbH (Germany).
Research Coverage:
This research report categorizes the molecular infectious disease testing market by product & service (reagents & kits, instruments, and services & software), by type (singleplex testing and multiplex testing), by test type (laboratory tests and point of car tests), by disease (respiratory infectious diseases (influenza, tuberculosis, pharyngitis, and other respiratory infectious diseases), gastrointestinal infectious diseases (hepatitis and other gastrointestinal infectious diseases), sexually transmitted diseases (human immunodeficiency virus, chlamydia trachomatis, neisseria gonorrhoea, syphilis, human papillomavirus, and other sexually transmitted diseases), vaginitis, meningitis, vector borne diseases, hospital-acquired infections, and other infectious diseases), by technology (polymerase chain reaction, in situ hybridization, isothermal nucleic acid amplification technology, DNA sequencing & next generation sequencing, DNA microarrays, and other technologies), by end user (diagnostic laboratories, hospitals & clinics, and other end users) and region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa, and the GCC countries). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the molecular infectious disease testing market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, key strategies, acquisitions, and agreements. New product & service launches, and recent developments associated with the molecular infectious disease testing market. Competitive analysis of upcoming startups in the molecular infectious disease testing market ecosystem is covered in this report.
Reasons to buy this report:
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall molecular infectious disease testing market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
• Analysis of key drivers (Rising burden of infectious diseases, rapid technological advancements in molecular diagnostics, growing funding for molecular testing), opportunities (High growth opportunities in emerging economies), restraints (Inconsistent reimbursement policies), and challenges (Changing regulatory landscape, operational barriers and labor shortage) influencing the growth of the molecular infectious disease testing market.
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the molecular infectious disease testing market.
• Market Development: Comprehensive information about lucrative markets – the report analyses the molecular infectious disease testing market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the molecular infectious disease testing market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings of leading players like Danaher (US), F. Hoffmann-La Roche Ltd (Switzerland), bioMérieux (France), Hologic, Inc. (US), and Abbott (US).

ページTOPに戻る

Table of Contents

1 INTRODUCTION 38
1.1 STUDY OBJECTIVES 38
1.2 MARKET DEFINITION 38
1.3 STUDY SCOPE 39
1.3.1 MARKET SEGMENTATION AND REGIONS COVERED 39
1.3.2 INCLUSIONS AND EXCLUSIONS 40
1.3.3 YEARS CONSIDERED 40
1.4 CURRENCY CONSIDERED 41
1.5 STAKEHOLDERS 41
2 RESEARCH METHODOLOGY 42
2.1 RESEARCH DATA 42
2.2 RESEARCH APPROACH 42
2.2.1 SECONDARY RESEARCH 42
2.2.1.1 Key secondary sources 43
2.2.1.2 Key data from secondary sources 43
2.2.1.3 Objectives of secondary research 43
2.2.2 PRIMARY RESEARCH 44
2.2.2.1 Key primary sources 44
2.2.2.2 Key data from primary sources 45
2.2.2.3 Objectives of primary research 46
2.2.2.4 Key industry insights 47
2.2.2.5 Breakdown of primary interviews 47
2.3 MARKET SIZE ESTIMATION 48
2.3.1 BOTTOM-UP APPROACH 49
2.3.1.1 Company revenue estimation approach 49
2.3.1.2 Presentations of companies and primary interviews 49
2.3.1.3 Estimation of total molecular-based tests for HIV in US 50
2.3.1.4 Growth forecast model 50
2.3.1.5 CAGR projections 51
2.3.2 TOP-DOWN APPROACH 51
2.4 DATA TRIANGULATION 52
2.5 MARKET SHARE ANALYSIS 53
2.6 RESEARCH ASSUMPTIONS 54
2.6.1 PARAMETRIC ASSUMPTIONS 54
2.6.2 GROWTH RATE ASSUMPTIONS 54
2.7 RESEARCH LIMITATIONS 55
2.8 RISK ANALYSIS 55
3 EXECUTIVE SUMMARY 56
4 PREMIUM INSIGHTS 62
4.1 MOLECULAR INFECTIOUS DISEASE TESTING MARKET OVERVIEW 62
4.2 MOLECULAR INFECTIOUS DISEASE TESTING MARKET,
BY PRODUCT & SERVICE, 2024 VS. 2029 62
4.3 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2024 VS. 2029 63
4.4 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2024 VS. 2029 63
4.5 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2024 VS. 2029 64
4.6 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY,
2024 VS. 2029 64
4.7 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2024 VS. 2029 65
4.8 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 65
5 MARKET OVERVIEW 66
5.1 INTRODUCTION 66
5.2 MARKET DYNAMICS 66
5.2.1 DRIVERS 67
5.2.1.1 Rising burden of infectious diseases 67
5.2.1.2 Rapid technological advancements in molecular diagnostics 68
5.2.1.3 Growing funding for molecular testing 69
5.2.2 RESTRAINTS 70
5.2.2.1 Inconsistent reimbursement policies 70
5.2.3 OPPORTUNITIES 70
5.2.3.1 High growth opportunities in emerging economies 70
5.2.4 CHALLENGES 71
5.2.4.1 Changing regulatory landscape 71
5.2.4.2 Operational barriers and labor shortage issues 72
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 72
5.4 PRICING ANALYSIS 73
5.4.1 INDICATIVE SELLING PRICE TREND, BY PRODUCT 73
5.4.2 INDICATIVE SELLING PRICE TREND OF SEXUALLY TRANSMITTED DISEASE TESTS, BY KEY PLAYER 73
5.4.3 INDICATIVE SELLING PRICE TREND OF GASTROINTESTINAL DISEASE TESTS, BY KEY PLAYER 74
5.4.4 INDICATIVE SELLING PRICE TREND, BY REGION 74
5.5 VALUE CHAIN ANALYSIS 75
5.6 SUPPLY CHAIN ANALYSIS 77
5.7 ECOSYSTEM ANALYSIS 78
5.8 INVESTMENT AND FUNDING SCENARIO 79

5.9 TECHNOLOGY ANALYSIS 80
5.9.1 KEY TECHNOLOGIES 80
5.9.1.1 Polymerase chain reaction 80
5.9.2 COMPLEMENTARY TECHNOLOGIES 81
5.9.2.1 Isolated nucleic acid amplification technology 81
5.9.3 ADJACENT TECHNOLOGIES 81
5.9.3.1 Next-generation sequencing 81
5.10 PATENT ANALYSIS 82
5.11 TRADE ANALYSIS 84
5.11.1 IMPORT DATA FOR HS CODE 3822 84
5.11.2 EXPORT DATA FOR HS CODE 3822 85
5.12 KEY CONFERENCES AND EVENTS, 2025–2026 85
5.13 CASE STUDY ANALYSIS 86
5.13.1 CASE STUDY 1: IMPROVED PATHOGEN-DIRECTED TREATMENT THROUGH RAPID SYNDROMIC PCR TESTING 86
5.13.2 CASE STUDY 2: CLINICAL IMPACT OF MULTIPLEX MOLECULAR DIAGNOSTIC TESTING IN CHILDREN WITH ACUTE GASTROENTERITIS 87
5.13.3 CASE STUDY 3: IMPACT OF MOLECULAR POINT OF CARE TESTING FOR
GROUP A STREPTOCOCCUS PHARYNGITIS 87
5.14 REGULATORY LANDSCAPE 88
5.14.1 REGULATORY ANALYSIS 88
5.14.1.1 NORTH AMERICA 88
5.14.1.1.1 US 88
5.14.1.1.2 Canada 88
5.14.1.2 EUROPE 88
5.14.1.2.1 Germany 89
5.14.1.2.2 UK 90
5.14.1.2.3 France 90
5.14.1.2.4 Italy 90
5.14.1.3 ASIA PACIFIC 91
5.14.1.3.1 China 91
5.14.1.3.2 Japan 91
5.14.1.3.3 India 91
5.14.1.3.4 Australia 92
5.14.1.4 LATIN AMERICA 92
5.14.1.4.1 Brazil 93
5.14.1.4.2 Mexico 93
5.14.1.5 MIDDLE EAST 93
5.14.1.5.1 Africa 93
5.14.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 94

5.15 PORTER’S FIVE FORCES ANALYSIS 95
5.15.1 BARGAINING POWER OF SUPPLIERS 97
5.15.2 BARGAINING POWER OF BUYERS 97
5.15.3 THREAT OF NEW ENTRANTS 97
5.15.4 THREAT OF SUBSTITUTES 97
5.15.5 INTENSITY OF COMPETITIVE RIVALRY 97
5.16 KEY STAKEHOLDERS AND BUYING CRITERIA 98
5.16.1 KEY STAKEHOLDERS IN BUYING PROCESS 98
5.16.2 BUYING CRITERIA 99
5.17 IMPACT OF AI ON MOLECULAR INFECTIOUS DISEASE TESTING MARKET 99
5.17.1 INTRODUCTION 99
5.17.2 MARKET POTENTIAL OF AI IN MOLECULAR INFECTIOUS DISEASE
TESTING APPLICATIONS 100
5.17.3 AI USE CASES 101
5.17.4 KEY COMPANIES IMPLEMENTING AI 102
5.17.5 FUTURE OF AI IN MOLECULAR INFECTIOUS DISEASE TESTING MARKET 102
6 MOLECULAR INFECTIOUS DISEASE TESTING MARKET,
BY PRODUCT & SERVICE 103
6.1 INTRODUCTION 104
6.2 REAGENTS & KITS 104
6.2.1 ONGOING INNOVATIONS IN MOLECULAR DIAGNOSTICS TO SPUR GROWTH 104
6.3 INSTRUMENTS 108
6.3.1 RISING PREVALENCE OF INFECTIOUS DISEASES TO FOSTER GROWTH 108
6.4 SERVICES & SOFTWARE 112
6.4.1 INCREASING UPTAKE OF ADVANCED INSTRUMENTS TO FACILITATE GROWTH 112
7 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE 116
7.1 INTRODUCTION 117
7.2 MULTIPLEX TESTING 117
7.2.1 RISING DEMAND FOR FASTER DIAGNOSIS TO PROMOTE GROWTH 117
7.3 SINGLEPLEX TESTING 121
7.3.1 NEED FOR AFFORDABLE AND USER-FRIENDLY TESTING TO AUGMENT GROWTH 121
8 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE 125
8.1 INTRODUCTION 126
8.2 LABORATORY TESTS 126
8.2.1 INCREASING NEED FOR AUTOMATION TO FAVOR GROWTH 126
8.3 POINT OF CARE TESTS 130
8.3.1 GROWING AWARENESS ABOUT DISEASE SURVEILLANCE, SCREENING, AND OUTBREAK RESPONSE TO DRIVE MARKET 130
9 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE 134
9.1 INTRODUCTION 135
9.2 RESPIRATORY INFECTIOUS DISEASES 136
9.2.1 INFLUENZA 139
9.2.1.1 Growing focus on faster diagnosis and control to propel market 139
9.2.2 TUBERCULOSIS 142
9.2.2.1 Rise in undiagnosed and untreated cases to promote growth 142
9.2.3 PHARYNGITIS 145
9.2.3.1 Need to differentiate between bacterial and viral infections to fuel growth 145
9.2.4 OTHER RESPIRATORY INFECTIOUS DISEASES 148
9.3 GASTROINTESTINAL INFECTIOUS DISEASES 150
9.3.1 HEPATITIS 153
9.3.1.1 Rising government initiatives to expedite growth 153
9.3.2 OTHER GASTROINTESTINAL INFECTIOUS DISEASES 156
9.4 SEXUALLY TRANSMITTED DISEASES 159
9.4.1 HUMAN IMMUNODEFICIENCY VIRUS 162
9.4.1.1 Increasing number of blood transfusions and blood donations to augment growth 162
9.4.2 HUMAN PAPILLOMAVIRUS 166
9.4.2.1 Technological advancements for preventing human papillomavirus infections to drive market 166
9.4.3 CHLAMYDIA TRACHOMATIS 169
9.4.3.1 Increasing development of molecular tests to aid growth 169
9.4.4 NEISSERIA GONORRHOEAE 172
9.4.4.1 Increasing development of novel assays to boost market 172
9.4.5 SYPHILIS 174
9.4.5.1 Growing demand for affordable and rapid molecular diagnostic solutions to drive market 174
9.4.6 OTHER SEXUALLY TRANSMITTED DISEASES 177
9.5 HOSPITAL-ACQUIRED INFECTIONS 180
9.5.1 GROWING BURDEN OF METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS TO FUEL MARKET 180
9.6 VAGINITIS 183
9.6.1 INCREASING AWARENESS ABOUT WOMEN’S HEALTH TO BOLSTER GROWTH 183
9.7 MENINGITIS 186
9.7.1 RISING INCIDENCE OF INVASIVE MENINGOCOCCAL DISEASE TO ASSIST GROWTH 186
9.8 VECTOR-BORNE DISEASES 188
9.8.1 GROWING FOCUS ON DISEASE SURVEILLANCE TO PROPEL MARKET 188
9.9 OTHER INFECTIOUS DISEASES 191

10 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY 195
10.1 INTRODUCTION 196
10.2 POLYMERASE CHAIN REACTION 197
10.2.1 NEED FOR HIGH PRECISION FOR DISEASE IDENTIFICATION TO SUPPORT GROWTH 197
10.3 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY 201
10.3.1 EMERGENCE OF NEW PATHOGENS TO STIMULATE GROWTH 201
10.4 DNA SEQUENCING & NEXT-GENERATION SEQUENCING 204
10.4.1 GROWING APPLICATIONS IN DIAGNOSING BACTERIAL, VIRAL, FUNGAL,
AND PARASITIC INFECTIONS TO DRIVE MARKET 204
10.5 IN SITU HYBRIDIZATION 207
10.5.1 NEED FOR SAFER AND MORE PRACTICAL TESTING IN CLINICAL SETTINGS TO FUEL MARKET 207
10.6 DNA MICROARRAYS 210
10.6.1 NEED FOR AFFORDABLE AND SENSITIVE DETECTION TO
ENCOURAGE GROWTH 210
10.7 OTHER TECHNOLOGIES 212
11 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER 215
11.1 INTRODUCTION 216
11.2 DIAGNOSTIC LABORATORIES 216
11.2.1 GROWING EMPHASIS ON QUALITY CONTROL AND STANDARDIZED
TESTING PROTOCOLS TO BOOST MARKET 216
11.3 HOSPITALS & CLINICS 219
11.3.1 RISING PATIENT VOLUME TO CONTRIBUTE TO GROWTH 219
11.4 OTHER END USERS 222
12 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY REGION 225
12.1 INTRODUCTION 226
12.2 NORTH AMERICA 226
12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 233
12.2.2 US 233
12.2.2.1 Presence of advanced healthcare infrastructure to augment growth 233
12.2.3 CANADA 238
12.2.3.1 Favorable government initiatives to fuel market 238
12.3 EUROPE 243
12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 248
12.3.2 GERMANY 248
12.3.2.1 Increasing healthcare expenditure to advance growth 248
12.3.3 UK 253
12.3.3.1 Growing number of diagnostic centers to fuel market 253
12.3.4 FRANCE 258
12.3.4.1 Increasing demand for early disease diagnosis to augment growth 258
12.3.5 ITALY 263
12.3.5.1 Growing adoption of advanced diagnostic technologies to
fuel market 263
12.3.6 RUSSIA 267
12.3.6.1 Increasing access to quality healthcare to facilitate growth 267
12.3.7 SPAIN 272
12.3.7.1 Growing public health initiatives to boost market 272
12.3.8 REST OF EUROPE 276
12.4 ASIA PACIFIC 281
12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 287
12.4.2 CHINA 288
12.4.2.1 Rising public access to modern healthcare to spur growth 288
12.4.3 JAPAN 293
12.4.3.1 Universal healthcare reimbursement policy to foster growth 293
12.4.4 INDIA 297
12.4.4.1 Increased private and public investments to bolster growth 297
12.4.5 AUSTRALIA 303
12.4.5.1 Growing investments for testing centers and treatment
facilities to drive market 303
12.4.6 REST OF ASIA PACIFIC 308
12.5 LATIN AMERICA 313
12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 318
12.5.2 BRAZIL 318
12.5.2.1 Growing focus on improving healthcare infrastructure to fuel market 318
12.5.3 MEXICO 323
12.5.3.1 Increasing accessibility and affordability of healthcare
services to foster growth 323
12.5.4 REST OF LATIN AMERICA 328
12.6 MIDDLE EAST & AFRICA 332
12.6.1 BOOMING HEALTHCARE INVESTMENTS TO AID GROWTH 332
12.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 337
12.7 GCC COUNTRIES 337
12.7.1 GROWING PUBLIC HEALTHCARE FUNDING TO DRIVE MARKET 337
12.7.2 MACROECONOMIC OUTLOOK FOR GCC COUNTRIES 341
13 COMPETITIVE LANDSCAPE 342
13.1 INTRODUCTION 342
13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 342
13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN MOLECULAR INFECTIOUS DISEASE TESTING MARKET 342
13.3 REVENUE ANALYSIS, 2021–2023 344
13.4 MARKET SHARE ANALYSIS, 2023 345
13.5 MARKET SHARE ANALYSIS OF EMEA REGION, 2023 347
13.6 COMPANY VALUATION AND FINANCIAL METRICS 347
13.7 BRAND/PRODUCT COMPARISON 348
13.8 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 349
13.8.1 STARS 349
13.8.2 EMERGING LEADERS 349
13.8.3 PERVASIVE PLAYERS 349
13.8.4 PARTICIPANTS 349
13.8.5 COMPANY FOOTPRINT, KEY PLAYERS, 2023 351
13.8.5.1 Company footprint 351
13.8.5.2 Region footprint 352
13.8.5.3 Product & service footprint 353
13.8.5.4 Test type footprint 354
13.8.5.5 Disease footprint 355
13.9 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 356
13.9.1 PROGRESSIVE COMPANIES 356
13.9.2 RESPONSIVE COMPANIES 356
13.9.3 DYNAMIC COMPANIES 356
13.9.4 STARTING BLOCKS 356
13.9.5 COMPETITIVE BENCHMARKING OF STARTUPS/SMES, 2023 358
13.9.5.1 Detailed list of key startups/SMEs 358
13.9.5.2 Competitive benchmarking of startups/SMEs 358
13.10 COMPETITIVE SCENARIO 359
13.10.1 PRODUCT LAUNCHES AND APPROVALS 359
13.10.2 DEALS 360
14 COMPANY PROFILES 362
14.1 KEY PLAYERS 362
14.1.1 DANAHER 362
14.1.1.1 Business overview 362
14.1.1.2 Products offered 363
14.1.1.3 Recent developments 365
14.1.1.3.1 Product launches and approvals 365
14.1.1.3.2 Deals 366
14.1.1.3.3 Expansions 366
14.1.1.4 MnM view 367
14.1.1.4.1 Right to win 367
14.1.1.4.2 Strategic choices 367
14.1.1.4.3 Weaknesses and competitive threats 367
14.1.2 F. HOFFMANN-LA ROCHE LTD 368
14.1.2.1 Business overview 368
14.1.2.2 Products offered 369

14.1.2.3 Recent developments 371
14.1.2.3.1 Product launches and approvals 371
14.1.2.3.2 Deals 372
14.1.2.3.3 Expansions 373
14.1.2.4 MnM view 373
14.1.2.4.1 Right to win 373
14.1.2.4.2 Strategic choices 373
14.1.2.4.3 Weaknesses and competitive threats 373
14.1.3 BIOMÉRIEUX 374
14.1.3.1 Business overview 374
14.1.3.2 Products offered 375
14.1.3.3 Recent developments 377
14.1.3.3.1 Product launches and approvals 377
14.1.3.3.2 Deals 378
14.1.3.4 MnM view 378
14.1.3.4.1 Right to win 378
14.1.3.4.2 Strategic choices 379
14.1.3.4.3 Weaknesses and competitive threats 379
14.1.4 HOLOGIC, INC. 380
14.1.4.1 Business overview 380
14.1.4.2 Products offered 381
14.1.4.3 Recent developments 382
14.1.4.3.1 Product launches and approvals 382
14.1.4.3.2 Deals 383
14.1.4.4 MnM view 383
14.1.4.4.1 Right to win 383
14.1.4.4.2 Strategic choices 384
14.1.4.4.3 Weaknesses and competitive threats 384
14.1.5 ABBOTT 385
14.1.5.1 Business overview 385
14.1.5.2 Products offered 386
14.1.5.3 Recent developments 388
14.1.5.3.1 Product launches and approvals 388
14.1.5.3.2 Deals 388
14.1.5.4 MnM view 389
14.1.5.4.1 Right to win 389
14.1.5.4.2 Strategic choices 389
14.1.5.4.3 Weaknesses and competitive threats 389
14.1.6 THERMO FISHER SCIENTIFIC INC. 390
14.1.6.1 Business overview 390
14.1.6.2 Products offered 391

14.1.6.3 Recent developments 392
14.1.6.3.1 Product launches and approvals 392
14.1.6.3.2 Deals 393
14.1.7 QIAGEN 394
14.1.7.1 Business overview 394
14.1.7.2 Products offered 395
14.1.7.3 Recent developments 396
14.1.7.3.1 Product launches and approvals 396
14.1.7.3.2 Deals 398
14.1.7.3.3 Expansions 398
14.1.8 REVVITY 399
14.1.8.1 Business overview 399
14.1.8.2 Products offered 401
14.1.9 GRIFOLS, S.A. 402
14.1.9.1 Business overview 402
14.1.9.2 Products offered 403
14.1.9.3 Recent developments 404
14.1.9.3.1 Product launches and approvals 404
14.1.9.3.2 Deals 404
14.1.10 SEEGENE INC. 405
14.1.10.1 Business overview 405
14.1.10.2 Products offered 406
14.1.10.3 Recent developments 407
14.1.10.3.1 Product launches and approvals 407
14.1.10.3.2 Deals 408
14.1.10.3.3 Expansions 409
14.1.11 DIASORIN S.P.A. 410
14.1.11.1 Business overview 410
14.1.11.2 Products offered 411
14.1.11.3 Recent developments 413
14.1.11.3.1 Product launches and approvals 413
14.1.11.3.2 Deals 414
14.1.12 SIEMENS HEALTHINEERS AG 415
14.1.12.1 Business overview 415
14.1.12.2 Products offered 416
14.1.12.3 Recent developments 417
14.1.12.3.1 Product launches and approvals 417
14.1.12.3.2 Deals 417
14.1.12.3.3 Expansions 418

14.1.13 BD 419
14.1.13.1 Business overview 419
14.1.13.2 Products offered 420
14.1.13.3 Recent developments 421
14.1.13.3.1 Product launches and approvals 421
14.1.13.3.2 Deals 423
14.1.13.3.3 Expansions 423
14.2 OTHER PLAYERS 424
14.2.1 QUIDELORTHO CORPORATION 424
14.2.2 BRUKER 426
14.2.3 GENETIC SIGNATURES 428
14.2.4 CO-DIAGNOSTICS, INC. 429
14.2.5 VELA DIAGNOSTICS 430
14.2.6 MOLBIO DIAGNOSTICS PVT. LTD. 431
14.2.7 SAVYON DIAGNOSTICS 433
14.2.8 UNIOGEN OY 434
14.2.9 GENEOMBIO TECHNOLOGIES 435
14.2.10 ADVANCED MOLECULAR DIAGNOSTICS 436
14.2.11 ALTONA DIAGNOSTICS GMBH 438
14.2.12 GENEFIRST LIMITED 439
15 APPENDIX 440
15.1 DISCUSSION GUIDE 440
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 445
15.3 CUSTOMIZATION OPTIONS 447
15.4 RELATED REPORTS 447
15.5 AUTHOR DETAILS 448